Anuh Pharma

Anuh Pharma EBITDA per Employee

The EBITDA per Employee of Anuh Pharma (ANUHPHR.NS) as of Oct 18, 2026 is 3.44 M INR. In the previous year, EBITDA per Employee was 4.43 M INR — a change of -22.27% (lower).

EBITDA per Employee

3.44 MINR

YoY

-22.27%

Last updated:

EBITDA per Employee of Anuh Pharma is 2026 3.44 M INR. EBITDA per Employee of Anuh Pharma was 2025 4.43 M INR. It decreases by -22.27% lower compared to the previous year.

The Anuh Pharma EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
2.15 M INR
Jan 1, 2020
1.89 M INR
Jan 1, 2021
2.80 M INR
Jan 1, 2022
3.27 M INR
Jan 1, 2023
3.61 M INR
Jan 1, 2024
5.49 M INR
Jan 1, 2025
4.43 M INR
Jan 1, 2026
3.44 M INR
The Anuh Pharma EBITDA per Employee history
YEAREBITDA per EmployeeYoY
3.44 MINR-22.27%
4.43 MINR-19.35%
5.49 MINR+52.03%
3.61 MINR+10.27%
3.27 MINR+16.72%
2.80 MINR+48.04%
1.89 MINR-11.87%
2.15 MINR+69.67%
1.27 MINR-8.86%
1.39 MINR-43.80%
2.47 MINR+19.34%
2.07 MINR+23.08%
1.68 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Anuh Pharma Stock analysis

What does Anuh Pharma do? Anuh Pharma Ltd is a pharmaceutical company based in Mumbai, India, operating within the healthcare sector. The company, which went public on April 19, 1995, employs 159 full-time staff. It specializes in the manufacturing of active pharmaceutical ingredients (APIs), focusing on various therapeutic categories including Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant, and Corticosteroids. The company produces specific products such as Erythromycin variants including Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate, and Azithromycin under its Macrolides segment. Anti-TB products include Pyrazinamide and Isoniazid. Anti-Malarial products consist of Sulfadoxine and Pyrimethamine. Anti-Bacterials include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products feature Losartan Potassium, Telmisartan, and Atorvastatin Calcium. The company also manufactures Ambroxol Hydrochloride as an Expectorant and Moxifloxacin Hydrochloride under Quinolones. Anuh Pharma Ltd maintains a corporate website at https://www.anuhpharma.com/ for further information about its operations and products. Anuh Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Anuh Pharma stock

EBITDA per Employee of Anuh Pharma is 3.44 M INR in 2026.

EBITDA per Employee of Anuh Pharma changed from 4.43 M INR to 3.44 M INR, representing a -22.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Anuh Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Anuh Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Anuh Pharma

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Anuh Pharma